THE ROLE OF PLASMA LEVELS INTERLEUKIN-6 ON MORTALITY IN NON-OBESE PATIENTS WITH NEWLY DIAGNOSED HEART FAILURE, DURING 12-MONTHS OF FOLLOW-UP